REGNHealthcareLarge-Cap
REGENERON PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for REGENERON PHARMACEUTICALS, INC. (REGN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are REGN insiders buying or selling?
REGENERON PHARMACEUTICALS, INC. insiders reported 0 open-market buys ($0) and 351 sells ($13.6B) across 351 Form 4 filings — a net selling position of $13.6B.
Source: SEC EDGAR Form 4
Key Statistics (as of Aug 12, 2026)
Total Form 4 filings
351
SEC EDGAR
Insider filers
22
Insider buys (0)
$0
Insider sells (351)
$13.6B
Insider sentiment
Net sellingNet insider flow of $13.6B in net selling.
Recent REGN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Kathryn Guarini | Director | Sale | 400 | $800.00 | $320.0K |
| Aug 12, 2026 | Huda Y Zoghbi | Director | Sale | 800 | $800.00 | $640.0K |
| Jul 7, 2026 | Arthur F Ryan | Director | Sale | 200 | $650.15 | $130.0K |
| May 4, 2026 | Arthur F Ryan | Director | Sale | 100 | $705.24 | $70.5K |
| Apr 3, 2026 | Arthur F Ryan | Director | Sale | 100 | $777.27 | $77.7K |
| Mar 3, 2026 | Arthur F Ryan | Director | Sale | 100 | $785.50 | $78.5K |
| Feb 23, 2026 | Huda Y Zoghbi | Director | Sale | 1.6K | $781.33 | $1.3M |
| Feb 11, 2026 | Jason Pitofsky | SVP Controller | Sale | 2.0K | $778.52 | $1.6M |
| Feb 11, 2026 | Arthur F Ryan | Director | Sale | 100 | $778.53 | $77.9K |
| Jan 8, 2026 | Bonnie L Bassler | Director | Sale | 1.5K | $800.00 | $1.2M |
| Nov 24, 2025 | Bonnie L Bassler | Director | Sale | 760 | $750.00 | $570.0K |
| Nov 10, 2025 | Jason Pitofsky | VP Controller | Sale | 431 | $651.43 | $280.8K |
| Oct 31, 2025 | Christine A Poon | Director | Sale | 6.5K | $654.27 | $4.3M |
| Nov 5, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $844.61 | $844.6K |
| Oct 3, 2024 | Arthur F Ryan | Director | Sale | 100 | $1048.78 | $104.9K |
| Oct 3, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $1054.06 | $1.1M |
| Sep 5, 2024 | Marion Mccourt | EVP Commercial | Sale | 1.0K | $1178.73 | $1.2M |
| Sep 5, 2024 | Arthur F Ryan | Director | Sale | 100 | $1178.69 | $117.9K |
| Aug 29, 2024 | Christopher R. Fenimore | SVP Finance & CFO | Sale | 5.7K | $1205.33 | $6.8M |
| Aug 19, 2024 | Bonnie L Bassler | Director | Sale | 756 | $1170.00 | $884.5K |
| Aug 19, 2024 | Christine A Poon | Director | Sale | 10.8K | $1158.17 | $12.6M |
| Aug 15, 2024 | Andrew J Murphy | EVP Research | Sale | 6.4K | $1153.15 | $7.3M |
| Aug 12, 2024 | Neil Stahl | EVP Research and Development | Sale | 5.2K | $1084.54 | $5.6M |
| Aug 7, 2024 | Jason Pitofsky | VP Controller | Sale | 487 | $1070.00 | $521.1K |
| Aug 5, 2024 | Bonnie L Bassler | Director | Sale | 756 | $1115.00 | $842.9K |
Showing the 25 most recent of 351 Form 4 filings for REGENERON PHARMACEUTICALS, INC..
Most active REGN insiders
- Arthur F Ryan53 filings
- Marion Mccourt45 filings
- Robert E Landry31 filings
- Joseph L Goldstein25 filings
- Bonnie L Bassler23 filings
Ask anything about REGN insider activity
Use Trabud's AI agent to query REGENERON PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me REGN CEO purchases this year" or compare it against any other ticker.
Open the AI agentREGN insider trading FAQ
Are REGENERON PHARMACEUTICALS, INC. insiders buying or selling?
Across 351 SEC Form 4 filings, REGENERON PHARMACEUTICALS, INC. (REGN) insiders reported 0 open-market purchases totaling $0 and 351 sales totaling $13.6B. That is a net selling position of $13.6B.
How many insiders trade REGN stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for REGENERON PHARMACEUTICALS, INC.. The most recent filing was accepted on Aug 12, 2026.
Where does Trabud get REGN insider trading data?
All REGN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.